Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 650 of 798 results for team work

  1. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113

    In development Reference number: GID-TA11025 Expected publication date: TBC

  2. NICE HealthTech programme manual (PMG48)

    This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme

  3. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

  4. Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (IPG666)

    Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.

  5. The OPTIMIZER smart system for managing heart failure (MIB186)

    NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .

  6. Pegcetacoplan for treating geographic atrophy [ID4041]

    In development Reference number: GID-TA11351 Expected publication date: TBC

  7. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued Reference number: GID-TAG239

  8. Buy books, journals and databases

    Our framework agreement allows UK NHS, health and social care organisations to buy knowledge resources that support practice, learning and development.

  9. Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

    In development Reference number: GID-TA10467 Expected publication date: TBC

  10. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development Reference number: GID-TAG388 Expected publication date: TBC

  11. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

  12. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

  13. Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

    In development Reference number: GID-TA10405 Expected publication date: TBC

  14. Thrombophilia [ID393]

    Discontinued Reference number: GID-TAG374

  15. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

  16. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .

  17. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  18. Slide sheets for moving or repositioning a person: late-stage assessment (HTG745)

    Late-stage assessment (LSA) guidance on slide sheets for moving or repositioning a person.

  19. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

  20. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  21. Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention (IPG766)

    Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.

  22. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

  23. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development Reference number: GID-TA11086 Expected publication date: TBC

  24. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

  25. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

  26. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

  27. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued Reference number: GID-TA10527

  28. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

  29. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

  30. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

  31. Harnessing digital innovation for children's mental health

    Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.

  32. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

  33. Hypertension in pregnancy: diagnosis and management (NG133)

    This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. It also includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies.

  34. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  35. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

  36. Events

    Our events help you meet experts and stay connected with peers.

  37. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development Reference number: GID-TA11228 Expected publication date: TBC

  38. CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment (HTG663)

    Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.

  39. What is the effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments?

    obstacle to the assessment processpractitioners from teams across health and social care need to work together on carers'...

  40. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  41. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

  42. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

  43. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development Reference number: GID-TA11277 Expected publication date: TBC

  44. MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)

    Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.

  45. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

  46. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

  47. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

  48. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

  49. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

  50. FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)

    Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.